Model-based intensification of CHO cell cultures: One-step strategy from fed-batch to perfusion.
CHO cells
bioprocess
fed-batch
intensification
mathematical modeling
perfusion
upstream
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
05
2022
accepted:
06
07
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
There is a growing interest in continuous processing of the biopharmaceutical industry. However, the technology transfer from traditional batch-based processes is considered a challenge as protocol and tools still remain to be established for their usage at the manufacturing scale. Here, we present a model-based approach to design optimized perfusion cultures of Chinese Hamster Ovary cells using only the knowledge captured during small-scale fed-batch experiments. The novelty of the proposed model lies in the simplicity of its structure. Thanks to the introduction of a new catch-all variable representing a bulk of by-products secreted by the cells during their cultivation, the model was able to successfully predict cellular behavior under different operating modes without changes in its formalism. To our knowledge, this is the first experimentally validated model capable, with a single set of parameters, to capture culture dynamic under different operating modes and at different scales.
Identifiants
pubmed: 36072286
doi: 10.3389/fbioe.2022.948905
pii: 948905
pmc: PMC9443430
doi:
Types de publication
Journal Article
Langues
eng
Pagination
948905Informations de copyright
Copyright © 2022 Richelle, Corbett, Agarwal, Vernersson, Trygg and McCready.
Déclaration de conflit d'intérêts
All authors are employees of Sartorius AG.
Références
Drug Discov Today. 2019 Sep;24(9):1795-1805
pubmed: 31207205
JAMA. 2020 Mar 03;323(9):844-853
pubmed: 32125404
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Clin Pharmacol Ther. 2020 Oct;108(4):756-761
pubmed: 32294230
Biotechnol Adv. 2022 Jan-Feb;54:107831
pubmed: 34480988
Biotechnol Prog. 2017 Jul;33(4):966-988
pubmed: 28401675
Curr Protoc Immunol. 2015 Nov 02;111:A3.B.1-A3.B.3
pubmed: 26529666
Nature. 2017 Dec 7;552(7683):S5
pubmed: 29219992
Biotechnol Adv. 2018 Jul - Aug;36(4):1328-1340
pubmed: 29738813
Biotechnol Prog. 2019 Mar;35(2):e2757
pubmed: 30479066
J Biotechnol. 2015 Aug 10;207:67-76
pubmed: 25956245
Trends Biotechnol. 2020 Aug;38(8):846-856
pubmed: 32493657
Biotechnol Prog. 2013 Jan-Feb;29(1):186-96
pubmed: 23143896
Biotechnol Prog. 2021 Jul;37(4):e3177
pubmed: 34036755
Eng Life Sci. 2016 Dec 12;17(4):440-447
pubmed: 32624789
Biotechnol J. 2019 Feb;14(2):e1700721
pubmed: 30024096
Curr Opin Chem Eng. 2021 Dec;34:None
pubmed: 34926134
Nat Rev Drug Discov. 2019 Jul;18(7):495-496
pubmed: 31267067
Trends Biotechnol. 2020 Oct;38(10):1141-1153
pubmed: 32518043
Nature. 2018 Apr;556(7700):263-265
pubmed: 29643487
Future Med Chem. 2020 May;12(10):939-947
pubmed: 32270704
Adv Biochem Eng Biotechnol. 2021;176:35-55
pubmed: 32797270
Trends Biotechnol. 2022 Jul;40(7):804-815
pubmed: 35034769